Inhibitor ribonukleotidne reduktaze

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu

Inhibitori ribonukleotidne reduktaze su familija antikancerni lekovi koji ometaju rast ćelija tumora blokiranjem formiranja dezoksiribonukleotida (gradivnih blokova DNK).

Primeri

Reference[uredi | uredi kod]

  1. Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). „Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)”. Biochem. Biophys. Res. Commun. 379 (3): 775–9. DOI:10.1016/j.bbrc.2008.12.128. PMID 19121624. 
  2. Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). „Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea”. Antivir. Chem. Chemother. 13 (5): 305–14. PMID 12630679. 
  3. Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). „Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies”. Expert Rev Anticancer Ther 2 (4): 437–48. DOI:10.1586/14737140.2.4.437. PMID 12647987. 
  4. Bernstein LR (1998). „Mechanisms of therapeutic activity for gallium”. Pharmacol. Rev. 50 (4): 665–682. PMID 9860806. Arhivirano iz originala na datum 2007-02-26. Pristupljeno 2014-07-08. 

Vidi još[uredi | uredi kod]

Vanjske veze[uredi | uredi kod]